Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The objective of the study is to determine the safely of Human Umbilical Cord Blood mononuclear cells by Intravenous injection in acute ischemic stroke patients.
Condition or disease
Acute Ischemic Stroke
Other: Human Umbilical Cord Blood mononuclear cells and 20% mannitol
The study will use Umbilical Cord Blood cells (a special kind of cell that is believed to be a stem cell) isolated from UCB (blood obtained at birth from the umbilical cord blood of babies). StemCyte, a leading accredited UCB banking company with branches in the United States and Taiwan, will provide the units of UCB that match at least 6 out of 6 HLA (human leukocyte antigens) for transplantation. The HLA-matching is the same as that used to match cells and organs for transplantation so that the body does not reject the cells. Then cells injection by Intravenous in acute ischemic stroke patients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
45 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
The age of Subjects between 45 through 80 years.
Acute Ischemic Stroke.
National Institutes of Health Stroke Scale (NIHSS):8-18(left brain ) or 8-15(right brain )
Brain MRI shows the middle cerebral artery region (M1 and M2) of cerebral i infarction stroke patients.
Subjects have no midline shift or hemorrhagic transformation
NIHSS score reduced more than 4 within after 12~24 hours.
Female are pregnant or lactating.
Subjects with impaired liver function, AIDS, cancer or other significant medical condition (including certifiable diseases, rare disease)
Subjects joined other clinical trails or received rt-PA therapy.
Immune dysfunction or receiving other immunosuppressive agents.
Subjects cannot have MRI test
Subjects' HLA typing results match less than 6 out of the 6 genotypes